The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

India Inc. is bracing for mixed Q3 results, with earnings growth expected to slow. Analysts predict a 2% Nifty EPS growth for ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

CLSA revised its rating for Bajaj Auto Ltd.'s share price to 'outperform' from 'underperform' earlier, after recent ...

Zypp Electric is in advanced talks to raise $25-30 million from investors led by Nuvama Wealth. Tribe Capital is ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

TARIL is undertaking an ambitious capacity expansion program, which will not only make the company India’s largest ...

The report said "Nifty EPS is likely to grow 2 per cent (versus 4 per cent in H1FY25)-posing downgrade risks to H2FY25 consensus estimate of mid-teens growth".

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...